Agilent Technologies Presents Thought Leader Award to Dr Lawrence Lesko
Agilent Technologies Inc. has announced that Dr. Lawrence J. Lesko from the University of Florida’s College of Pharmacy in Orlando, USA, has received an Agilent Thought Leader Award for his research into preclinical toxicological assessments of new medicines.
Agilent Technologies Inc. (Santa Clara, California, USA) has announced that Dr. Lawrence J. Lesko, of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida’s College of Pharmacy in Orlando, USA, has received an Agilent Thought Leader Award for his research into preclinical toxicological assessments of new medicines.
Dr. Lesko and his team are working to identify novel biomarkers that can help drug makers better assess new drug candidates and can also potentially enable doctors to better manage treatments.
Monty Benefiel, Agilent vice president and general manager of the Mass Spectrometry Division, said: “We are pleased to support Dr. Lesko’s research, which is addressing important needs in the rapidly evolving field of systems toxicology.”
“I am very pleased and appreciative of Agilent’s Thought Leader Award,” said Dr. Lesko. “It enables our team to identify metabolomic safety biomarkers of drug-induced renal toxicity and the mechanisms by which these toxicities occur. This research will lead us to identifying at-risk patients and exploring the use of concomitantly administered medicines as protectants against drug-induced renal damage. It could have a major effect on improving drug development and clinical care.”
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
